Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062524 | 0.90 | MEN1 (0.58) | MEN1KMT2AACHECHRM2GRIN2B | |
| SCHEMBL1078739 | 0.90 | MEN1 (0.57) | MEN1KMT2AACHECHRM2GRIN2B | |
| SCHEMBL1063078 | 0.90 | MEN1 (0.56) | MEN1KMT2AACHECHRM2GRIN2B | |
| SCHEMBL3831715 | 0.85 | ACHE (0.57) | MEN1KMT2AACHECHRM2SMN1; SMN2 | |
| SCHEMBL1063365 | 0.85 | MEN1 (0.66) | MEN1KMT2AGRIN2BSMN1; SMN2ALDH1A1 | |
| SCHEMBL1063370 | 0.85 | MEN1 (0.66) | MEN1KMT2ACHRM2GRIN2BSMN1; SMN2 | |
| SCHEMBL1079888 | 0.85 | MAPK14 (0.63) | MEN1KMT2AACHESMN1; SMN2ALDH1A1 | |
| SCHEMBL14337827 | 0.84 | MEN1 (0.66) | MEN1KMT2ACHRM2GRIN2BSMN1; SMN2 | |
| SCHEMBL14559862 | 0.84 | LMNA (0.62) | MEN1KMT2AACHECHRM2SMN1; SMN2 | |
| SCHEMBL1063934 | 0.84 | MEN1 (0.54) | MEN1KMT2ACHRM2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189739-B2 | Compounds and methods to treat cardiac failure and other disorders | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | MEN1 3843/4885KMT2A 4668/4885ACHE 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.